AHB-171

AHB-171 is a subcutaneously administered antisense oligonucleotide (ASO) being developed by Ausper Biopharma for the treatment of chronic hepatitis B (CHB). Utilizing proprietary technology, AHB-171 is designed to specifically target and degrade all Hepatitis B Virus (HBV) RNA transcripts. This mechanism leads to the potent suppression of all viral proteins, most notably the hepatitis B surface antigen (HBsAg), which plays a critical role in viral persistence and the suppression of the host immune response. By significantly reducing the viral protein load, AHB-171 aims to restore the patient's innate and adaptive immune systems, potentially leading to a functional cure for HBV infection. It is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and pharmacokinetics in healthy volunteers and CHB patients.